By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014 11:02:52 AM
Aymeric Le Chatelier Joins Ipsen (IPN.PA) As Executive Vice President, Chief Financial Officer 10/10/2014 8:32:34 AM
Susheel Surpal Steps Down As Executive Vice President, Chief Financial Officer Of Ipsen (IPN.PA) To Pursue Other Opportunities 10/2/2014 10:39:22 AM
Ipsen (IPN.PA) Presents Preliminary Results Of Exploratory Proof-Of-Concept Study With Tasquinimod In Four Advanced Tumor Types At The ESMO 2014 Congress 9/29/2014 12:05:48 PM
Ipsen (IPN.PA) Announces Acceptance Of Filings For Somatuline® In The Treatment Of GEP-NET1s In The U.S. With Priority Review And In Europe 9/2/2014 12:03:26 PM
Ipsen (IPN.PA): 2014 Half-Year Results And 2014 Objectives 8/29/2014 12:10:47 PM
Ipsen (IPN.PA) Announces Second Resupply Of Increlex® (Mecasermin [Rdna Origin] Injection) In The U.S. In 2014 8/26/2014 8:30:08 AM
Ipsen (IPN.PA) Appoints Cynthia Schwalm As President And CEO Of Ipsen North America 8/20/2014 9:12:03 AM
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014 10:59:14 AM
Ipsen (IPN.PA) And Galderma Laboratories Become Exclusive Partners For Development And Marketing Of Neurotoxins In The US, Canada, Brazil And Europe 7/11/2014 9:08:57 AM